Article Document Academic Article Information Content Entity Continuant Continuant Journal Article Entity Entity Generically Dependent Continuant 2025-05-11T20:09:28 RDF description of Benefits of dexmedetomidine in management of post-ECT agitation - http://repository.healthpartners.com/individual/document-rn7386 10.1097/yct.0000000000000393 Drugs and Drug Therapy 3 33 13605 public Benefits of dexmedetomidine in management of post-ECT agitation <p>Electroconvulsive therapy (ECT) is an intervention for patients with a variety of psychiatric conditions. Occasionally, people exhibit dangerous degrees of agitation after this treatment, and some do not respond well to conventional pharmacotherapies. Dexmedetomidine is a central alpha-2 agonist that can induce significantly calmative effects in persons with post-ECT agitation. The indication for it is in calming individuals with acute and/or recurrent posttreatment agitation. Dexmedetomidine is safe and effective when infused just before, or postictally, at ECT sessions.<p> 2022-02-21T22:48:57.408-06:00 Journal of ECT Adverse Effects Mental Disorders 21790 document-rn7386